Legend Biotech (LEGN) Current Deferred Revenue (2019 - 2025)

Legend Biotech has reported Current Deferred Revenue for 7 years, with the latest figure at $11.3 million in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue fell 75.91% year-over-year to $11.3 million; the trailing twelve-month figure through Dec 2025 stood at $11.3 million (down 75.91% YoY), and the FY2025 full-year result was $11.3 million, down 75.91% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $11.3 million, down from $22.6 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $245.8 million in Q1 2022, with the low at -$60.6 million in Q4 2021.
• Historically, Current Deferred Revenue has averaged $59.3 million across 5 years, with a median of $43.2 million in 2024.
• The largest YoY upside for Current Deferred Revenue was 96471.42% in 2021 against a maximum downside of 210.23% in 2021.
• Legend Biotech's Current Deferred Revenue stood at -$60.6 million in 2021, then jumped by 505.4% to $245.8 million in 2022, then plunged by 78.44% to $53.0 million in 2023, then retreated by 11.53% to $46.9 million in 2024, then sank by 75.91% to $11.3 million in 2025.
• The last three Current Deferred Revenue figures came in at $11.3 million (Q4 2025), $22.6 million (Q3 2025), and $33.2 million (Q2 2025), per Business Quant data.